18:40
Bagsvrd, Denmark, 8 October 2020 Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.

In the third quarter of 2020, Novo Nordisks sales increased by 7% and operating profit increased by 7%, both at CER. This reflects lower than anticipated negative impacts from COVID-19 as well as underlying market demand. Sales growth was positively impacted by inventory changes at wholesaler level in the US.